Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/den.12603 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase I/II trial of intracerebral transplantation of autologous bone marrow stem cells combined with recombinant peptide scaffold for patients with chronic intracerebral haemorrhage: a study protocol.
BMJ Open
December 2024
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Article Synopsis
- Intracerebral hemorrhage (ICH) is a major cause of death and disability globally, with few treatment options, prompting research into the potential of stem cell therapies, specifically using bone marrow stromal cells (BMSCs) combined with scaffolds.
- The RAINBOW-Hx trial aims to evaluate the safety and effectiveness of this treatment in eight patients with chronic ICH, focusing on those with significant neurological deficits for over a year.
- The study has received ethical approval and involves detailed procedures like bone marrow extraction, cell cultivation, and various imaging assessments post-treatment to monitor patient outcomes.
Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.
Clin Transl Sci
December 2024
Shanghai LianBio Development Co., Ltd, Shanghai, China.
Infigratinib, an FGFR1-3 selective oral tyrosine kinase inhibitor, has shown clinical activity in cancers with FGFR alterations. The pharmacokinetics (PK) of infigratinib and its major metabolites have been characterized in global populations. This study examined the PK profile of infigratinib and its metabolites in Chinese patients.
View Article and Find Full Text PDFSafety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study.
Clin Exp Vaccine Res
October 2024
YS Biopharma (Singapore) Co. Ltd., Singapore, Singapore.
Article Synopsis
- The study assessed the safety and effectiveness of a new COVID-19 booster vaccine (PIKA-adjuvanted recombinant) for adults who have already received two doses of an inactivated vaccine.
- Participants were divided into two groups: one received the PIKA vaccine, while the other got an inactivated vaccine, with their safety monitored and immune response measured through antibody levels over time.
- Results showed that the PIKA vaccine significantly increased neutralizing antibodies against both the Omicron variant and the original SARS-CoV-2 virus shortly after vaccination, although there was no long-term difference in antibody levels between the two vaccines after 90 days.
A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor.
Neurooncol Adv
September 2024
Brain Tumor Center, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
Background: Atypical and anaplastic meningiomas account for 20% of all meningioma cases. Solitary fibrous tumor (SFT) is a type of soft tissue sarcoma with similar attributes to meningioma. For patients with refractory or recurrent disease after previous surgery or radiotherapy, there is no effective treatment.
View Article and Find Full Text PDFEnoxaparin and Early Postoperative Tibial Nailing: Increased Nonunion Revision Rates.
J Orthop Trauma
October 2024
Oregon Health & Science University, Portland, OR.
Article Synopsis
- The study aimed to explore whether using enoxaparin after surgery impacts the likelihood of needing additional surgery for nonunion in patients who had intramedullary nailing for tibial midshaft fractures.
- Utilizing a retrospective cohort design, researchers analyzed data from the PearlDiver national database, focusing on patients treated between 2015 and 2020 who required revision surgery.
- Findings revealed that enoxaparin use was linked to higher nonunion rates for certain fracture types, indicating it may influence postoperative outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!